Discrimination of Kidney Cancer Subtypes

Discriminating important sub-types of kidney cancer is very challenging using current pathological methods. This discrimination is important when there is a difference between benign and malignant kidney cancer.

ChemImage’s Raman Molecular Imaging (RMI) approach enables differentiation between benign and malignant tissues which, using standard methods, appear the same.

Why Use RMI for this Application?

• There are no established methods for discrimination between oncocytoma and
  chromophobe renal cell carcinomas.
• The distinction is important because while one form is benign, the other is malignant.
• RMI has been shown to discriminate these two types of cancer.

Raman molecular images are acquired and analyzed using established chemometric based classification methods to determine whether the cancer is benign or malignant.

Want to know more? Download the ChemImage & Allegheny General Hospital, Department of Urology joint poster: "Diagnostic Utility of Raman Molecular Imaging (RMI) in Separating Renal Oncocytoma from
Chromophobe Renal Cell Carcinoma"

Reagentless RMI Based Discrimination of Benign vs. Maligant Kidney Tissues

FALCON II™

• Features
• Specifications
• Applications
• FAQ's
• Image Gallery

• Application Notes
• Posters